Active substance
Results for the substance beta agalsidase
2 results
About this active substance
Agalsidase beta is a medication used for the treatment of Fabry disease, a rare genetic disorder characterized by the accumulation of globotriaosylceramide in cells. It is an enzyme replacement therapy that helps break down this substance and prevent organ damage.
It is administered via intravenous infusion, usually once every two weeks, under the supervision of a specialist. Treatment with agalsidase beta can improve patients' quality of life by reducing symptoms and slowing disease progression.
Side effects may include infusion site reactions, fever, chills, or muscle pain. In rare cases, severe allergic reactions may occur.
Patients should be regularly monitored to assess the effectiveness of the treatment and to identify any adverse reactions. It is essential to follow the doctor's recommendations to achieve the best outcomes.
It is administered via intravenous infusion, usually once every two weeks, under the supervision of a specialist. Treatment with agalsidase beta can improve patients' quality of life by reducing symptoms and slowing disease progression.
Side effects may include infusion site reactions, fever, chills, or muscle pain. In rare cases, severe allergic reactions may occur.
Patients should be regularly monitored to assess the effectiveness of the treatment and to identify any adverse reactions. It is essential to follow the doctor's recommendations to achieve the best outcomes.